A Phase 1b/2 Study of Idelalisib in Combination With BI 836826 in Subjects With Chronic Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs BI 836826 (Primary) ; Idelalisib (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 28 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 08 May 2017 Planned End Date changed from 1 Sep 2023 to 1 Jan 2018.
- 08 May 2017 Planned primary completion date changed from 1 Nov 2021 to 1 Jan 2018.